Evidence map›Paper›PMID 28301282›Full record

Trial reportHuman vaccines & immunotherapeutics2017

Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial.

Yongliang Feng, Jing Shi, Linying Gao, Tian Yao, Dan Feng, Dan Luo, Zhansheng Li, Yawei Zhang, Fuzhen Wang, Fuqiang Cui and 3 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02959775 (Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02959775 phase4completednot on this map

Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial

TypeinterventionalSponsorShanxi Medical UniversityRan2014 to 2015Enrolled480ConditionsHepatitis B VaccinationArms60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. [Expert recommendations on hepatitis B vaccination in adults].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Yongliang Fenga School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Jing Shia School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Linying Gaoa School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Tian Yaoa School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Dan Fenga School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Dan Luob Yongji Center for Disease Control and Prevention , Yongji, Shanxi , China.
Zhansheng Lib Yongji Center for Disease Control and Prevention , Yongji, Shanxi , China.
Yawei Zhangc Yale School of Medicine , New Haven , CT , USA.
Fuzhen Wangd Chinese Center for Disease Control and Prevention , Beijing , China.
Fuqiang Cuid Chinese Center for Disease Control and Prevention , Beijing , China.
Li Lid Chinese Center for Disease Control and Prevention , Beijing , China.
Xiaofeng Liangd Chinese Center for Disease Control and Prevention , Beijing , China.
Suping Wanga School of Public Health, Shanxi Medical University , Taiyuan, Shanxi , China.
Shanxi Medical University · CNChinese Center For Disease Control and Prevention · CNYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the low uptake, adherence, and completion of vaccination among drug users, and their compromised immune responses to hepatitis B vaccination, the current practice of hepatitis B vaccination may not provide optimal protection. The aim of this study was to evaluate the immunogenicity and safety of 60 µg and 20 µg hepatitis B vaccines among drug users. A randomized, open-labeled, blank-controlled trial was conducted among drug users at 2 drug rehabilitation centers in China. The eligible participants were drug users who were serologically negative for the hepatitis B surface antigen (HBsAg) and the hepatitis B surface antibody (anti-HBs). Participants were randomized in a ratio of 1:1:1 to receive 20 µg (IM20 group) or 60 µg (IM60 group) of hepatitis B vaccine or blank control at months 0, 1, and 6, and followed at months 6, 7, and 12. Seroconversion rates of 94.7% and 92.6% were observed in IM20 and IM60 groups at month 7, and correspondingly decreased to 89.5% and 91.7% respectively at month 12. The IM60 group showed significantly higher geometric mean concentrations (GMCs) of anti-HBs (2022.5 and 676.7 mIU mL-1) than the IM20 group did (909.6 and 470.5 mIU mL-1) at months 7 and 12 (P < 0.05). No safety concerns associated with vaccination were noted. Three-dose intramuscular immunization with hepatitis B vaccines showed good immunogenicity among the drug users.

Indexed as

AdolescentAdultAgedChinaDrug UsersFemaleHepatitis BHepatitis B AntibodiesHepatitis B VaccinesHumansInjections, IntramuscularMaleMiddle AgedSeroconversionSubstance-Related DisordersYoung AdultHepatitis B AntibodiesHepatitis B Vaccinesdrug abuseHepatitis Bimmunogenicityrandomized controlled trialvaccination

Identifiers

PMID28301282
PMCPMC5489281
OpenAlexW2597069222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.